Use of Japanese encephalitis vaccine in children : recommendations of the Advisory Committee on Immunization Practices, 2013
Published Date:November 15, 2013
Corporate Authors:United States. Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.) ; National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Vector-Borne Diseases.
Encephalitis, Japanese/prevention & Control
Japanese Encephalitis Vaccines/adverse Effects
Japanese Encephalitis Vaccines/immunology
Japanese Encephalitis Vaccines/therapeutic Use
Randomized Controlled Trials As Topic
Vaccines, Inactivated/adverse Effects
Vaccines, Inactivated/therapeutic Use
Series:MMWR. Morbidity and mortality weekly report ; v. 62, no. 45, p. 898-900
Description:On June 19, 2013, the Advisory Committee on Immunization Practices (ACIP) voted to extend existing recommendations for use of inactivated Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC) (Ixiaro, Intercell Biomedical) to include children aged 2 months through 16 years. The ACIP JE Vaccine Workgroup reviewed the epidemiology of JE in travelers and evaluated published and unpublished data on JE-VC immunogenicity and safety in adults and children. The evidence for benefits and risks associated with JE-VC vaccination of children was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. This report summarizes the evidence considered by ACIP and outlines the recommendations for use of JE-VC in children traveling to JE-endemic countries.
Citation: Centers for Disease Control and Prevention (CDC). Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013. MMWR Morb Mortal Wkly Rep. 2013 Nov 15;62(45):898-900.
Supporting Files:No Additional Files
You May Also Like: